Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Maia Biotechnology Inc MAIA

Healthcare Biotechnology
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces... see more

Recent & Breaking News (NYSEAM:MAIA)

MAIA Biotechnology to Present at Biotech Showcase 2025

Business Wire 10 hours ago

MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications

Business Wire 3 days ago

MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

Business Wire December 19, 2024

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

Business Wire December 16, 2024

MAIA Biotechnology Announces Private Placement of Approximately $950,000

Business Wire December 9, 2024

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer

Business Wire December 3, 2024

MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement

Business Wire November 7, 2024

MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Business Wire November 5, 2024

MAIA Biotechnology Announces $2.44 Million Private Placement

Business Wire October 28, 2024

MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics

Business Wire October 15, 2024

MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer

Business Wire September 10, 2024

MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire September 4, 2024

MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

Business Wire July 23, 2024

MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy

Business Wire June 7, 2024

MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent

Business Wire June 6, 2024

MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer

Business Wire June 4, 2024

MAIA Biotechnology to Present at the BIO International Convention 2024

Business Wire May 17, 2024

MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

Business Wire May 16, 2024

MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement

Business Wire April 30, 2024

MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement

Business Wire April 29, 2024